Rigel Pharmaceuticals, Inc. (RIGL)
39.65
-6.06
(-13.26%)
USD |
NASDAQ |
Nov 06, 16:00
39.60
-0.05
(-0.13%)
After-Hours: 20:00
Rigel Pharmaceuticals Price to Book Value : 1.739 for Nov. 6, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 1.739 |
| November 05, 2026 | 2.004 |
| November 04, 2026 | 2.249 |
| November 03, 2026 | 2.142 |
| November 02, 2026 | 2.216 |
| October 30, 2026 | 2.250 |
| October 29, 2026 | 2.256 |
| October 28, 2026 | 2.225 |
| October 27, 2026 | 2.216 |
| October 26, 2026 | 2.188 |
| October 23, 2026 | 2.110 |
| October 22, 2026 | 2.142 |
| October 21, 2026 | 2.143 |
| October 20, 2026 | 2.110 |
| October 19, 2026 | 2.049 |
| October 16, 2026 | 2.016 |
| October 15, 2026 | 2.072 |
| October 14, 2026 | 2.053 |
| October 13, 2026 | 2.067 |
| October 12, 2026 | 2.140 |
| October 09, 2026 | 2.152 |
| October 08, 2026 | 2.136 |
| October 07, 2026 | 2.104 |
| October 06, 2026 | 2.022 |
| October 05, 2026 | 2.096 |
| Date | Value |
|---|---|
| October 02, 2026 | 2.067 |
| October 01, 2026 | 2.060 |
| September 30, 2026 | 2.111 |
| September 29, 2026 | 2.144 |
| September 28, 2026 | 2.164 |
| September 25, 2026 | 2.113 |
| September 24, 2026 | 2.100 |
| September 23, 2026 | 2.110 |
| September 22, 2026 | 2.141 |
| September 21, 2026 | 2.065 |
| September 18, 2026 | 2.045 |
| September 17, 2026 | 2.010 |
| September 16, 2026 | 1.950 |
| September 15, 2026 | 1.945 |
| September 14, 2026 | 1.988 |
| September 11, 2026 | 2.071 |
| September 10, 2026 | 2.073 |
| September 09, 2026 | 2.070 |
| September 08, 2026 | 2.077 |
| September 04, 2026 | 2.134 |
| September 03, 2026 | 2.127 |
| September 02, 2026 | 2.167 |
| September 01, 2026 | 2.083 |
| August 31, 2026 | 2.025 |
| August 28, 2026 | 2.038 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Cytokinetics, Inc. | -- |
| Inovio Pharmaceuticals, Inc. | 22.89 |
| United Therapeutics Corp. | 3.795 |
| Verastem, Inc. | 15.22 |
| Marker Therapeutics, Inc. | 1.224 |
Price to Book Value Related Metrics
| PE Ratio | 2.429 |
| PS Ratio | 2.801 |
| PEG Ratio | 0.0121 |
| Price to Free Cash Flow | 85.74 |
| Price | 39.65 |
| Earnings Yield | 41.17% |
| Market Cap | 739.63M |
| PEGY Ratio | 0.0121 |
| Operating PE Ratio | 8.905 |
| Normalized PE Ratio | 2.428 |